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Disease biomarkers are defined to diagnose various phases of diseases, monitor severities of diseases and responses
to therapies, or predict prognosis of patients. Disease-specific biomarkers should benefit drug discovery and
development, integrate multidisciplinary sciences, be validated by molecular imaging. The opportunities and
challenges in biomarker development are emphasized and considered. The Journal of Translational Medicine opens
a new Section of Disease Biomarkers to bridge identification and validation of gene or protein-based biomarkers,
network biomarkers, dynamic network biomarkers in human diseases, patient phenotypes, and clinical applications.
Disease biomarkers are also important for determining drug effects, target specificities and binding, dynamic
metabolism and pharmacological kinetics, or toxicity profiles.The word “biomarker” describes a traceable and charac-
terized substance that is an indicator of biological
morphology, processes and function. Disease biomarkers
are used to diagnose various phases of diseases, monitor
severities of diseases and responses to therapies, and are
predictors of prognosis of patients and likely responses
to therapy. One of criteria to evaluate the value of
disease biomarkers is the disease-associated specificity,
sensitivity, traceability, stability, repeatability and reli-
ability. Increasing numbers of biomarkers are being dis-
covered and identified from preclinical research, but
only a few have been found to be useful clinically. The
Journal of Translational Medicine opens a new Section
of Disease Biomarkers to bridge identification and valid-
ation of gene or protein-based biomarkers, network bio-
markers, dynamic network biomarkers in human
diseases, patient phenotypes, and clinical applications.
The Section intends to accelerate the discovery and de-
velopment of human disease-specific biomarkers for the
early diagnosis, evaluation of diseases and predictions of
responses to therapy. The Section will be an important
and critical platform to underscore the significance and* Correspondence: xiangdong.wang@clintransmed.org
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reproduction in any medium, provided the orvalue of Disease Biomarkers and promote innovation
and development of disease-specific biomarkers by
integrating multidisciplinary aspects of science. The
following are aspects of the planned biomarker studies:
a) Benefitting drug development: Disease biomarkers can
play critical roles not only in clinical applications but
also in drug discovery and development as related to
drug efficacy or toxicity, allowing selection of “the
right drugs and the right patients” [1]. For example,
more than 90% of new anti-cancer drugs in clinical
trials have failed marketing approval, often due to
poor efficacies and efficiencies, high toxicities, drug
resistance or unexpected safety issues. The lack of
disease-specific biomarkers is one of major
challenges, often making it difficult to predict drug
efficacy. The Section of Disease Biomarkers will
accelerate the procedure of biomarker identification
and validation for determining drug effects, target
specificities and binding, dynamic metabolism and
pharmacological kinetics, toxicity profiles, or side-
effects. In addition, Disease Biomarkers will
emphasize the importance of molecular and cellular
responses to drugs under pathophysiological
conditions, creating a new concept of “the right
biomarker, the right drug and the right patient”. Thisis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mechanisms of interactions between biomarkers,
drugs and diseases. Optimal biomarkers should allow
monitoring drug efficacy and safety and individual
responses to specific treatments. Patients evaluated
and treated at the early stage of disease may enhance
business decisions related to drug development,
facilitating regulatory approval for new therapies [2].
Quantification and safety of biomarkers are necessary
for final decisions related to new drug development
and applications.
b) Integration of multidisciplinary sciences:
Identification, validation, development and marketing
of disease-specific biomarkers need to integrate
processes in molecular biology, new biotechnologies,
clinical sciences, regulatory policies, and clinical
applications. “Omic” science and technology play
important roles in the identification and discovery of
biomarkers. The Omic scope includes genomics,
proteomics, metabolomics, pharmacogenomics,
transcriptomics, and other high-throughput
methodologies. Selected biomarker candidates can be
validated using computational biology, high-
throughput image analysis, molecular genetics,
specimens from human tissue banks, mathematical
medicine and biology, protein expression and
profiling, and systems biology. Clinical bioinformatics
have been suggested as a new way to combine
clinical measurements and signs with human tissue-
generated bioinformatics, helping to understand the
role of selected biomarker candidates in clinical
settings, disease development and progression, and
therapeutic strategies, and mapping relationships of
drug and biomarker candidates with clinical
examinations, pathology data, biochemical analysis,
imaging, and therapies [3]. For example, locations of
targeted biomarkers are validated in human is
tissues, using imaging data of tumor regions in
various lung compartments. Selectivity and precision
of proteomic analyses were performed in patients
with chronic lung diseases and cancer [4]. Panels of
disease-specific protein biomarkers that define the
disease stage were selected in chronic obstructive
pulmonary disease. By targeted proteomic analysis, a
digital evaluation score system was developed for
assessing the severity of the disease, clinical
information, and lung function [5,6]. A number of
new integrated scientific areas have been created
during the identification and development of disease-
specific biomarkers. Genomic medicine was
proposed to bring biomarkers into the mainstream of
clinical practice and improve therapies and quality of
patient life, although such strategies are in the very
early stages. Systems clinical medicine has beendefined as one of new strategic areas for
development of disease biomarkers, involving
integration of systems biology, clinical phenotypes,
high-throughout technologies, bioinformatics and
computational science in order to improve diagnosis,
prognosis and therapies of diseases [7]. Next
generation sequencing for genomic analysis of
individual genomes has been used for single
nucleotide polymorphism discovery and estimates of
allele frequency, gene ontology analysis of the target
genes, analysis of the microRNAs expression,
sequencing platforms for mRNA biomarker analysis,
genome-wide analysis, and the exploration of the
proteome, all of which should lead to the
identification of useful protein biomarkers.
c) Significance of molecular imaging in validation of
biomarkers: It has been suggested that selected
biomarker candidates need to be validated in human
tissues, (e.g. measuring the expression of targeted
mRNA and proteins in pathological tissues of
patients) as well as correlating the over-expression of
targeted candidates with dysfunction of organs or
tissues. Tissue microarray analysis is a powerful tool
for validation of biomarker candidates, especially
with an algorithm-tissue array co-occurrence matrix
analysis for quantifying cellular phenotypes based on
textural regularity by local inter-pixel configurations
[8]. In addition, matrix-assisted laser desorption/
ionization mass spectrometry imaging is used for
spatial distribution and relative abundance of
molecules directly in tissues in order to improve the
quality of molecular images and differentiate tissue
regions that cannot be morphologically defined. It
has been suggested that such imaging may be
beneficial for disease diagnosis and prognosis,
biomarker discovery and drug therapy, even though
there are still many barriers. As an example, clinical
phenotypes and severities of chronic obstructive
pulmonary disease were measured by the parametric
response map, a voxel-wise image analysis technique
of whole-lung using computed tomography that
results in more accurate diagnosis of individual
patients, together with integration of clinical
information [9]. Numerous imaging technologies
have been applied for biomarker validation and
development, including near infrared imaging,
neuronuclear imaging, whole-body diffusion
magnetic resonance imaging, specific biomarker
detection on the cell surface in real time, positron
emission tomography, molecular contrast-enhanced
ultrasound imaging, and acceptor fluorescence
anisotropy that measures variations in hetero-
fluorescence resonance energy transfer deriving from
protein-protein interactions.
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biomarkers: Multiple biomarkers were found to
improve the prediction of death from cardiovascular
causes during a more than 10 year follow-up of
patients, suggesting that simultaneous presence of
biomarkers in cardiovascular disease as well as
presence of established risk factors substantially
improves the risk stratification for death from
cardiovascular disease in elderly men [10]. Network
biomarkers and dynamic network biomarkers
represent new types of biomarkers with interactions
between proteins or genes that can be monitored
and evaluated at different stages and time points
during development of disease [11]. The amount of
high-throughput genomic and proteomic data from
patients has been rapidly increasing and is expected
to correlate with clinical phenotypes, disease
severities, therapeutic responses, and prognoses.
Gene regulatory networks or protein interaction
networks may describe functions for the panel of
relevant network biomarkers. Dynamic network
biomarkers can demonstrate changes at various
stages in diseases and seem to have disease
specificity. Disease biomarkers need to be validated
by integration with clinical informatics, which
translates clinical descriptive information on signs,
symptoms, biochemical analyses, imaging and
therapies into digital data [5,6]. Clinical
bioinformatics may be helpful in discovering disease-
specific, stage-specific, severity-specific and/or
therapy-predictive biomarkers.
e) Challenges in development: As one of major
technologies for biomarker identification and
discovery, genomics and proteomics as well as
sequencing still face a large number of challenges,
(e.g., analysis of the individual’s genome in the
context of extensive population-based data,
phenotypic significance and specificity, duration and
severity, of disease, genomic or proteomic variation,
combinations of genomic, expression-based,
metabolomic, and proteomic data, and the value of
disease biomarkers for making clinical decision).
Some tissue microarrays have been questioned due
to study sizes, reduced throughput, variability, and
expenses related to the observations. A recent study
combined genome-wide association with forced
expiratory volume in 1 second and the ratio of
forced expiratory volume in 1 second to forced vital
capacity, identified 16 new genomic regions showing
association with pulmonary function [12]. Those
biomarkers were selected from 48,201 individuals of
European ancestry, with follow up of top associations
in an additional 46,411 individuals. However, there is
further need to better understand the biomarkersassociated with molecular mechanisms involving
pulmonary function and validate selected targets in
order to reduce lung dysfunction.
Conclusions
The Section of Disease Biomarkers is expected to accel-
erate the process from identification to validation, re-
search to development, resulting in improved design of
clinical trials. There should also be positive impacts on
governmental approval, and clinical applications to
policy and regulation, and relevance to “personalized”
medicine and to public health. The Section will publish
articles related to development of advanced biotechnolo-
gies for biomarker discovery, the biomarkers associated
with the early detection of diseases, and monitoring of
disease severity and duration as well as patient responses
to therapies, predictions of patient outcomes and life
qualities, the clinical trial and evaluation of biomarkers,
and regulation and ethics of disease biomarkers.
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